IDEXX Laboratories, Inc. (IDXX) Shares Bought by Sei Investments Co.
Sei Investments Co. boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 28.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 55,806 shares of the company’s stock after acquiring an additional 12,360 shares during the period. Sei Investments Co.’s holdings in IDEXX Laboratories were worth $8,727,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of IDXX. Atlantic Trust Group LLC purchased a new stake in IDEXX Laboratories in the 3rd quarter valued at about $65,381,000. Old Mutual Global Investors UK Ltd. raised its holdings in IDEXX Laboratories by 60.1% in the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 830,379 shares of the company’s stock valued at $129,115,000 after buying an additional 311,712 shares during the period. American Century Companies Inc. raised its holdings in IDEXX Laboratories by 48.7% in the 3rd quarter. American Century Companies Inc. now owns 715,175 shares of the company’s stock valued at $111,203,000 after buying an additional 234,197 shares during the period. Bank of New York Mellon Corp raised its holdings in IDEXX Laboratories by 30.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 955,225 shares of the company’s stock valued at $148,527,000 after buying an additional 220,818 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in IDEXX Laboratories in the 3rd quarter valued at about $23,806,000. Hedge funds and other institutional investors own 86.02% of the company’s stock.
Shares of IDEXX Laboratories, Inc. (IDXX) opened at $187.61 on Monday. The company has a debt-to-equity ratio of -11.26, a quick ratio of 0.80 and a current ratio of 0.97. The stock has a market cap of $16,345.11, a PE ratio of 59.37, a price-to-earnings-growth ratio of 2.31 and a beta of 0.58. IDEXX Laboratories, Inc. has a one year low of $141.02 and a one year high of $198.73.
Several analysts recently issued reports on the stock. Canaccord Genuity restated a “buy” rating and issued a $210.00 price objective on shares of IDEXX Laboratories in a report on Monday, January 29th. BidaskClub upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Tuesday, January 16th. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $214.00 price objective on the stock in a report on Monday, February 5th. Piper Jaffray Companies boosted their price objective on shares of IDEXX Laboratories to $211.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Finally, Aegis restated a “sell” rating on shares of IDEXX Laboratories in a report on Friday, December 8th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the stock. IDEXX Laboratories presently has a consensus rating of “Buy” and a consensus target price of $194.00.
In other IDEXX Laboratories news, Director William T. End sold 4,000 shares of the business’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $184.48, for a total transaction of $737,920.00. Following the sale, the director now directly owns 41,256 shares in the company, valued at $7,610,906.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Brian P. Mckeon sold 6,602 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $181.36, for a total transaction of $1,197,338.72. Following the sale, the vice president now owns 47,040 shares in the company, valued at $8,531,174.40. The disclosure for this sale can be found here. Insiders have sold 90,762 shares of company stock worth $15,940,404 over the last quarter. Insiders own 2.77% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “IDEXX Laboratories, Inc. (IDXX) Shares Bought by Sei Investments Co.” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/idexx-laboratories-inc-idxx-shares-bought-by-sei-investments-co/1891342.html.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.